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ABSTRACT
Non-tuberculous mycobacteria (NTM) are ubiquitous
environmental organisms that can cause chronic
pulmonary infection, particularly in individuals with pre-
existing inﬂammatory lung disease, such as cystic ﬁbrosis
(CF). Pulmonary disease (PD) caused by NTM has
emerged as a major threat to the health of individuals
with CF, but remains difﬁcult to diagnose and
problematic to treat. In response to this challenge, the
US Cystic Fibrosis Foundation (CFF) and the European
Cystic Fibrosis Society (ECFS) convened a panel of 19
experts to develop consensus recommendations for the
screening, investigation, diagnosis and management of
NTM-PD in individuals with CF. PICO (population,
intervention, comparison, outcome) methodology and
systematic literature reviews were employed to inform
draft recommendations, which were then modiﬁed to
achieve consensus and subsequently circulated for public
consultation within the USA and European CF
communities. We have thus generated a series of
pragmatic, evidence-based recommendations as an initial
step in optimising management for this challenging
condition.
BACKGROUND
Non-tuberculous mycobacteria (NTM) are increas-
ingly being isolated from the sputum of adults and
children with cystic ﬁbrosis (CF) both in North
America and Europe. Estimates of the prevalence
of NTM in the CF population have ranged from
1.3% in the earliest study reported in 19841 to
32.7% in a review of patients with CF over age 40
in Colorado.2
The NTM species most commonly identiﬁed in
individuals with CF from North America and
Europe are the slow growing Mycobacterium avium
complex (MAC, including M. avium, M. intracellu-
lare and M. chimaera), which can be found in up to
72% of NTM-positive sputum cultures, and the
rapid growing M. abscessus complex (comprising
the subspecies M. abscessus subsp abscessus
(M. a. abscessus), M. a. bolletii and M. a. massiliense
(the latter currently classiﬁed as part of
M. a. bolletii)), which in many centres has now
become the most common NTM isolated from indi-
viduals with CF.
There has been a rise in the prevalence of
NTM-positive cultures in respiratory samples from
individuals with CF over the last three decades,
which probably reﬂects a true increase in the fre-
quency of NTM infection. A number of CF studies
(eg, Renna et al3) show year-on-year increases in
NTM-positive cultures with no change in surveil-
lance intensity or culture methodology.
Possible reasons for increased NTM-positive cul-
tures in individuals with CF include: increases in
environmental exposure to NTM through more
permissive temperature settings of home water
heaters and more contact with shower aerosols,
increased antibiotic usage creating more NTM per-
missive lung niches, greater chronic use of medica-
tions that might impair host immunity to NTM3
and/or spread of NTM through person-to-person
transmission.4
NTM can cause progressive inﬂammatory lung
damage, a condition termed ‘NTM pulmonary
disease’ (NTM-PD), which is deﬁned by the pres-
ence of speciﬁc microbiological, clinical and radio-
logical features.5 However, it has become clear that
NTM can also transiently, intermittently or per-
manently reside within the lungs of CF individuals
without causing NTM-PD, thus representing
asymptomatic infection and creating considerable
difﬁculties in deciding how best to screen for and
diagnose NTM.
Further challenges exist in knowing how best to
identify NTM in respiratory samples, when and
how to initiate treatment for NTM-PD and how
NTM may impact individuals under consideration
for lung transplantation. As a consequence, the
Cystic Fibrosis Foundation (CFF) and European
Cystic Fibrosis Society (ECFS) sought to generate a
consensus recommendations document to support
and standardise the management of NTM infection
in children and adults with CF, permitting
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prospective evaluation of current best practice and forming a
foundation for future research programmes.
METHODS
The CFF and the ECFS invited experts to participate in the
statement development process. The 19 member committee
consisted of professionals with expertise in CF and NTM and
included adult and paediatric CF physicians, lung transplant
physicians, microbiologists, infectious disease specialists and a
parent of an individual with CF. The committee convened in
May 2012 and divided into ﬁve subgroups, each responsible for
a speciﬁc topic: epidemiology and risk factors, screening,
Figure 1 Cystic Fibrosis Foundation and European Cystic Fibrosis Society recommendations on non-tuberculous mycobacteria (NTM) management
in cystic ﬁbrosis (CF).








microbiology, treatment and transplantation. Each subgroup
developed topic-speciﬁc questions using the PICO format
(population, intervention, comparison, outcome). Questions
were reviewed and approved by the entire committee before sys-
tematic literature searches were conducted.
The members of each subgroup used the PICO questions to
guide literature searches in PubMed. Searches were limited to
English language and the period 1984–2013. Subgroup
members also searched for topic relevant guidelines through
searches of the ATS website, the IDSA website, the Clinical
Laboratory Standards Institute website and the UK CF Trust
website.
After reviewing relevant literature and existing guidelines,
subgroup members drafted recommendation statements. In
October 2012, a second meeting was convened, and subgroups
ﬁnalised draft recommendation statements. The committee also
voted to set 80% agreement of all 19 members as the threshold
for acceptance of a recommendation statement.
Each subgroup submitted ﬁnal draft questions for entry into
an electronic survey tool (Survey Monkey) for the purposes of
anonymous voting and comment by all members. A project
coordinator administered the survey, and committee members
were asked to rate each statement on a scale of 0 (completely
disagree) to 9 (completely agree), with 80% or between 7 and 9
being considered ‘good’ agreement. Space for entering free text
was also provided after each statement to allow members to cite
literature in support of their opinions or suggested revisions. All
committee members were required to vote on each statement
regardless of their role or expertise. Multiple rounds of voting
and revisions to the statements were conducted, and for each
round committee members were requested to complete their
voting within 3 weeks. The committee chairs reviewed the
results from each round and updated the statements based on
comments entered by respondents for subsequent rounds.
A draft of the recommendations was presented at the 2013
North American Cystic Fibrosis Conference and the ECFS
Meeting. In addition, the committee solicited feedback from the
CF communities in the USA and Europe, which included physi-
cians, nurses, physical and respiratory therapists, parents and
individuals with CF. Comments collected from this process were
considered by the committee in the development of the ﬁnal
recommendation statements.
RESULTS
Three rounds of voting were conducted to achieve 80% consen-
sus for each statement. Fifty-three statements were included in
the ﬁrst round of voting and 50 statements in the second and
third rounds. Final statements are shown in ﬁgure 1.
DISCUSSION
The management of individuals with CF infected with NTM is
extremely challenging. The limited amounts of published
research and clinical trial data provide inadequate evidence to
base management decisions on how best to screen, diagnose,
detect and treat NTM-PD. As a response to this urgent clinical
need, the CF Foundation and ECFS formed a committee of clin-
icians, scientists and infectious disease experts to develop
recommendations to guide and assist clinicians in the manage-
ment of NTM-PD in individuals with CF. The committee
believe these recommendations should serve as a benchmark for
current medical care while providing a framework to inform the
development of clinical, translation and basic research studies to
generate robust evidence to base future iterations of these
management guidelines leading to better outcomes for indivi-
duals with CF infected with NTM.
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